<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>354</serviceExecutionTime><Drug id="8417"><DrugName>L-695256</DrugName><DrugSynonyms><Name><Value>L-695256</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>137154-16-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18077">Merck &amp; Co Inc</CompanyOriginator><CompaniesSecondary><Company id="18077">Merck &amp; Co Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="8417" type="Drug"><TargetEntity id="177073" type="siDrug">L-695256</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="138" type="ciIndication"><TargetEntity id="D016908" type="MeSH"></TargetEntity><TargetEntity id="-2050266020" type="omicsDisease"></TargetEntity><TargetEntity id="808" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="138">Gram positive bacterium infection</Indication><Indication id="308">Staphylococcus aureus infection</Indication><Indication id="40">Bacterial infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="73547">Carbapenem</Action><Action id="104">Bacterial cell wall synthesis inhibitor</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J1P2</Code><Name>Carbapenems</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-04T05:12:55.000Z</LastModificationDate><ChangeDateLast>2004-12-07T17:50:16.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="8417" linkType="Drug"&gt;L-695256&lt;/ulink&gt; is a beta-lactam antibiotic from Merck. The development of the compound has been discontinued due to low water solubility, but the carbapenem (qv) program is still ongoing [&lt;ulink linkID="162481" linkType="reference"&gt;162481&lt;/ulink&gt;], [&lt;ulink linkID="347790" linkType="reference"&gt;347790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Details of &lt;ulink linkID="8417" linkType="Drug"&gt;L-695256&lt;/ulink&gt;'s in vitro testing were presented at ICAAC in 1994 [&lt;ulink linkID="162481" linkType="reference"&gt;162481&lt;/ulink&gt;], [&lt;ulink linkID="163174" linkType="reference"&gt;163174&lt;/ulink&gt;], [&lt;ulink linkID="163175" linkType="reference"&gt;163175&lt;/ulink&gt;], [&lt;ulink linkID="163177" linkType="reference"&gt;163177&lt;/ulink&gt;], along with bacterial resistance development data [&lt;ulink linkID="163178" linkType="reference"&gt;163178&lt;/ulink&gt;], [&lt;ulink linkID="163179" linkType="reference"&gt;163179&lt;/ulink&gt;] and information on the compound's binding to penicillin-binding proteins [&lt;ulink linkID="163181" linkType="reference"&gt;163181&lt;/ulink&gt;]. In vivo studies had been conducted in the mouse infection model [&lt;ulink linkID="163182" linkType="reference"&gt;163182&lt;/ulink&gt;], as well as clearance studies in rhesus monkeys and chimpanzees [&lt;ulink linkID="163183" linkType="reference"&gt;163183&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;This 2-aryl carbapenem showed good in vitro activity against multiple-resistant Gram-positive bacteria [&lt;ulink linkID="163177" linkType="reference"&gt;163177&lt;/ulink&gt;], with an MIC90 value against MRSA, equal to &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt; at 2 microg/ml. However, due to its efficient binding to PBP-2a (IC50 = 0.4 microg/ml) [&lt;ulink linkID="163181" linkType="reference"&gt;163181&lt;/ulink&gt;], and its short half-life of 1 h in chimpanzees (which is expected to be the same in humans), &lt;ulink linkID="8417" linkType="Drug"&gt;L-695256&lt;/ulink&gt;, is considered to be a prototype 2-arylcarbapenem, which is unsuitable as monotherapy. The short half-life would result in sub-lethal quantities of antibiotic for a longer period of time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><ExpertReview>&lt;para&gt;Joanne Orrick, Pharm D and Thomas Johns, Pharm D, Shands at &lt;ulink linkType="Company" linkID="20575"&gt;University of Florida&lt;/ulink&gt;, Gainesville, USA&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;11 August 1998&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; is a synthetic carbapenem antibiotic from &lt;ulink linkType="Company" linkID="18077"&gt;Merck &amp;amp; Co&lt;/ulink&gt; currently undergoing preclinical testing for the treatment of Gram-positive and Gram-negative infections. This compound is a 2 aryl-carbapenem that binds to penicillin binding proteins (PBPs) to inhibit bacterial cell wall synthesis [&lt;ulink linkType="reference" linkID="163181"&gt;163181&lt;/ulink&gt;]. The potential for this compound to be used in the treatment of multiple-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) is of interest [&lt;ulink linkType="reference" linkID="163177"&gt;163177&lt;/ulink&gt;]. Due to the emergence of MRSA strains with intermediate susceptibility to &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, there has been heightened interest in developing new drugs with activity against this pathogen. PBP-2a has been identified as the protein that mediates staphylococcal resistance to methicillin. The level of affinity for PBP-2a correlates with ability to inhibit cell wall synthesis in experimental strains of MRSA. Compounds such as &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; that bind PBP-2a with a high degree of affinity are likely be effective in the treatment of infections caused by MRSA [&lt;ulink linkType="reference" linkID="173398"&gt;173398&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; is a prototype carbapenem that differs from traditional beta-lactam antibiotics due to a very hydrophobic aryl group at position 2 that is further substituted with a formally cationic species [&lt;ulink linkType="reference" linkID="162481"&gt;162481&lt;/ulink&gt;]. Since high level Staphylococcus aureus (S aureus) methicillin-resistance is mediated by PBP-2a, a 96-well-filter binding assay, using recombinant PBP-2a has been developed for the kinetic measurement of antibiotic binding affinities. The results with several compounds correlated well with the electrophoretic assay for PBP-2a using membranes from methicillin-resistant S aureus [&lt;ulink linkType="reference" linkID="288137"&gt;288137&lt;/ulink&gt;]. The concentrations of &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt;, penicillin, and imipenem that inhibited binding of radiolabeled penicillin to the PBP-2a by 50% were 1.2, 14, and 68 microg/ml, respectively. The concentrations of &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt;, penicillin, and imipenem that inhibited cell wall synthesis for the methicillin-resistant strain, COL, by 50% were 1.3, 2.6, and 132 microg/ml, respectively [&lt;ulink linkType="reference" linkID="173398"&gt;173398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; binds with high affinity to the PBP-2a, the protein responsible for methicillin resistance in S aureus. &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; shows in vitro activity against Gram-negative and Gram-positive organisms, including MRSA. Measuring in vitro activity using the agar dilution method showed that &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; is less active than imipenem against Enterobacteriaceae, but more active against Proteus mirabilis and Morganella morganii. &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; was highly active against methicillin-resistant and -sensitive S aureus (MIC 0.016 to 2 microg/ml). &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; is also highly active against penicillin-resistant pneumococci (MIC 0.016 to 0.064 microg/ml) [&lt;ulink linkType="reference" linkID="187270"&gt;187270&lt;/ulink&gt;]. In a comparative study of the in vitro activity against Gram-positive bacteria, all streptococci and oxacillin-susceptible staphylococci were inhibited at concentrations of =&amp;lt; 0.125 microg/ml, and oxacillin-resistant strains at concentrations =&amp;lt; 4 microg/ml. Growth was completely inhibited by 4 microg/ml of &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; while growth was inhibited by 100 microg/ml of penicillin and imipenem [&lt;ulink linkType="reference" linkID="187225"&gt;187225&lt;/ulink&gt;]. The in vivo activity of &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; was compared to that of imipenem, penicillin, and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; in a rabbit aortic valve endocarditis model of the methicillin-resistant strains, COL and 76. The efficacies of &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; 10 mg/kg tid, imipenem 37.5 mg/kg tid, penicillin 300,000 units/kg tid, and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; 25 mg/kg bid, were compared. Mean bacterial densities in the aortic valve vegetations were reduced as follows after 4 days of drug therapy: 4.0 to 5.8, 1.0 to 1.8, -1.1 to 3.9, and 1.1 to 3.0 log10 CFU/g for &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt;, imipenem, penicillin, and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, respectively [&lt;ulink linkType="reference" linkID="173398"&gt;173398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;The pharmacokinetic parameters of &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; were compared to that of imipenem in rhesus monkeys and chimpanzees. Compared to imipenem, &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; has a larger area under the curve (30 versus 24 microg.h/ml in the rhesus monkey and 77 compared to 60 microg.h/ml in the chimpanzee). &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; also has a longer half-life than imipenem (1.2 compared to 0.6 h in the rhesus monkeys and 1.0 compared to 0.8 h in the chimpanzee) [&lt;ulink linkType="reference" linkID="210507"&gt;210507&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Hemolytic anemia characterized by extravascular hemolysis and splenomegaly was induced in rhesus monkeys given &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; 50 or 200 mg/kg/day, iv, for 2 weeks. A subsequent study showed that the hemolytic anemia was immune-mediated since all rhesus monkeys given 100 mg/kg/day iv for 4 weeks were direct antiglobulin test (Coombs' test)-positive for IgG with a 20 to 25% reduction in erythron. The erythron returned to normal after 3 weeks. In a study in squirrel monkeys treated for 2 weeks with 200 mg/kg/day iv, all animals remained Coomb's test-negative and no changes in the erythron were observed. This suggested that the immune-mediated hemolytic anemia may be species specific to the rhesus monkey [&lt;ulink linkType="reference" linkID="289960"&gt;289960&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;No data are currently available.  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Recently, there have been two approaches to antimicrobial drug development in response to the continual evolution of bacteria resistant to the currently available agents. Due to the increased resistance of S aureus and the recent isolation of MRSA strains with decreased susceptibility to &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, there has been particular interest in developing antimicrobial agents with activity against MRSA. One approach has been the development of new antimicrobial agents with novel mechanisms of action. One such agent is &lt;ulink linkType="Drug" linkID="11036"&gt;linezolid&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="18995"&gt;Pharmacia &amp;amp; Upjohn&lt;/ulink&gt;), an oxazolidinone antibiotic which has a novel mechanism of action. Another approach has been modification of classical antibiotics by targeting the microbial resistance factors. &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; is a prototype carbapenem antibiotic with activity against MRSA. This activity is due to its high affinity for PBP-2a which is responsible for S aureus resistance to methicillin. &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; shows good in vitro activity against Gram-negative bacteria, including Proteus mirabilis and Morganella morganii. However, it shows less activity than imipenem against Enterobacteriaceae. In addition, &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; is highly active against methicillin-sensitive and -resistant S aureus as well as penicillin-resistant pneumococci. A significant toxicity of &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; seen in rhesus monkeys is immune-mediated hemolytic anemia. This toxicity was not seen when further tested in squirrel monkeys and was reversible by 3 weeks upon discontinuation of &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt;. At this time, it cannot be concluded that this toxicity will not occur in humans. Currently, &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; is the only agent approved by &lt;ulink linkType="Company" linkID="28926"&gt;the FDA&lt;/ulink&gt; for the treatment of MRSA. Therefore, &lt;ulink linkType="Drug" linkID="8417"&gt;L-695256&lt;/ulink&gt; seems to be a promising antimicrobial agent for the treatment of infections due to MRSA but its further development will depend on the efficacy and, more importantly, the safety of competing compounds that are on the horizon.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-11-17T00:00:00.000Z</StatusDate><Source id="347790" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="138">Gram positive bacterium infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-11-17T00:00:00.000Z</StatusDate><Source id="347790" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-11-17T00:00:00.000Z</StatusDate><Source id="347790" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="138">Gram positive bacterium infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)[O-])c3ccc4c(c3)-c5ccc(cc5C4=O)C[n+]6ccn(c6)C)O</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2053111" number="WO-09406764" title="Preparation of beta-methyl carbapenem intermediates."></PatentFamily><PatentFamily id="386653" number="EP-00472306" title="2-(9-Fluorenonyl)-Carbapenem Antibacterial Agents"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>